Public trial registry of the CCC-Munich

Trial Destiny Breast-02

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
Destiny Breast-02
World
Full title
:

A PHASE 3, MULTICENTER, RANDOMIZED, OPEN LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (DS-8201A), AN ANTIHER2-ANTIBODY DRUG CONJUGATE, VERSUS TREATMENT OF INVESTIGATOR’S CHOICE FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH T-DM1 DS8201-A-U301

World
Responsible organization
:
Frauenklinik Frauenklinik Ismaninger Str. 22 81675 München Germany
Indications
Classification Code Description
- Breastcancer
Trial design
World
Phase
:
III
Status
World
Status
:
Recruitment finished
Votes
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / Unknown
Therapy
World
Therapy
:

Zielgerichtet - Therapieart: palliativ

Participants
Function Prename Surname Organization
World Responsible contact Johannes Ettl Frauenklinik Frauenklinik Ismaninger Str. 22 81675 München Germany Magnifier